Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × pyrotinib × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 57 HER2-positive Breast Cancer 15 HER2 Positive Metastatic Breast Cancer 3 HER2 Positive Breast Cancer 3 Breast Diseases 3 Brain Neoplasms 3 Advanced Breast Cancer 3 HER2-positive Metastatic Breast Cancer 2 Breast Cancer Invasive 2 Breast Cancer Female 2 Triple Negative Breast Neoplasms 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Metastatic Breast Cancer in the Brain 1 Locally Advanced Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-positive Advanced Breast Cancer 1 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1 HER2+ Early or Locally Advanced Breast Cancer 1 HER2+ Breast Cancer 1 Estrogen Receptor-positive Breast Cancer 1 Breast Neoplasm Female 1 Breast Cancer Metastatic 1

Interventions

Capecitabine 47 Paclitaxel 41 Trastuzumab 33 Fulvestrant 28 pembrolizumab 24 Cyclophosphamide 23 Carboplatin 23 Letrozole 19 Gemcitabine 19 palbociclib 18 Docetaxel 18 exemestane 17 Lapatinib 16 Bevacizumab 15 eribulin 14 Everolimus 13 Magnetic Resonance Spectroscopy 12 Anastrozole 12 abemaciclib 11 Vinorelbine 11 Nivolumab 11 Cisplatin 11 trastuzumab deruxtecan 10 Tamoxifen 10 Albumin-Bound Paclitaxel 10 Specimen Handling 9 Radiotherapy 9 Doxorubicin 9 olaparib 8 Zoledronic Acid 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04355858 2022-07-26

MULAN

Fudan University

Phase 2 Unknown

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡